Q4 2025 MaxCyte Inc Earnings Call Transcript
Key Points
- MaxCyte Inc (MXCT) successfully integrated SeQure DX, enhancing its business operations.
- The company launched the ExPERT DTx platform, which is expected to drive growth by enabling seamless transitions from discovery to clinical stages.
- MaxCyte Inc (MXCT) maintained a strong balance sheet with $155.6 million in cash and no debt, providing financial flexibility.
- The company reported a high gross margin of 78% in Q4 2025, indicating efficient cost management.
- MaxCyte Inc (MXCT) continues to sign new Strategic Platform Licenses (SPLs), supporting more late-stage programs than ever before, which could lead to future revenue growth.
- Total revenue for 2025 declined by 15% compared to 2024, indicating financial challenges.
- The company faced a $4 million revenue headwind due to customer program consolidations and rationalizations.
- MaxCyte Inc (MXCT) experienced a 22% decrease in core revenue in Q4 2025 compared to the same period in 2024.
- The company lost six SPL clinical programs in 2025, impacting future revenue potential.
- Guidance for 2026 indicates continued revenue challenges, with expectations of a decline in core revenue compared to 2025.
Good day, everyone, and welcome to MaxCyte's fourth quarter earnings conference call. (Operator Instructions) Please note, this conference is being recorded.
Now I'll turn the call over to [Eric Abdel] with Investor Relations. Please proceed.
Good afternoon, everyone. Thank you for participating in today's conference call. Joining me on the call from MaxCyte, we have Maher Masoud, President and Chief Executive Officer; Doug Swirsky, Chief Financial Officer; and Sean Menarguez, Senior Director of Business Development.
Earlier today, MaxCyte released financial results for the fourth quarter and full year ended December 31, 2025. A copy of the press release is available on the company's website. Before we begin, I need to read the following statement. Statements or comments made during this call may be forward-looking statements within the meaning of federal securities laws. Any statements contained in this call that relate to expectations or predictions of future events, results or performance are forward
| Access to All Earning Calls and Stock Analysis | |
| 30-Year Financial on one screen | |
| All-in-one Stock Screener with unlimited filters | |
| Customizable Stock Dashboard | |
| Real Time Insider Trading Transactions | |
| 8,000+ Institutional investors’ 13F holdings | |
| Powerful Excel Add-in and Google sheets Add-on | |
| All data downloadable | |
| Quick customer support | |
| And much more... |
Trustpilot
We'd love to learn more about your experiences on GuruFocus.com and how we can improve!
Take Survey
